LabCorp to acquire clinical trials firm Chiltern for $1.2bn
The transaction will help LabCorp create leading expertise in the oncology segment by combining the extensive experience of Covance in late phase with the deep expertise of Chiltern
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research and development (R&D).